Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal

[1]  A. Chander,et al.  Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal , 2013, BMC Research Notes.

[2]  M. Banjara,et al.  Antimicrobial Susceptibility Pattern of Escherichia coli Isolated from Uninary Tract Infected Patients Attending Bir Hospital , 2013 .

[3]  S. Khanal,et al.  β-Lactamase-Producing Multidrug-Resistant Bacterial Pathogens from Tracheal Aspirates of Intensive Care Unit Patients at National Institute of Neurological and Allied Sciences, Nepal , 2013, ISRN microbiology.

[4]  B. Shrestha,et al.  Plasmid profiling of multidrug resistant Escherichia coli strains isolated from urinary tract infection patients , 2013 .

[5]  Jaspal Kaur,et al.  Modified Double Disc Synergy Test to Detect ESBL Production in Urinary Isolates of Escherichia coli and Klebsiella pneumoniae. , 2013, Journal of clinical and diagnostic research : JCDR.

[6]  M. Hamid,et al.  Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan. , 2013, African health sciences.

[7]  Lin Gan,et al.  Direct Optical Characterization of Graphene Growth and Domains on Growth Substrates , 2012, Scientific Reports.

[8]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  B. Lekhak,et al.  High prevalence of multidrug resistance in bacterial uropathogens from Kathmandu, Nepal , 2012, BMC Research Notes.

[10]  M. Timinouni,et al.  Emergence of extended-spectrum beta-lactamases-producing Escherichia coli in community-acquired urinary infections in Casablanca, Morocco. , 2011, Journal of infection in developing countries.

[11]  Judith A. Johnson,et al.  Clinical laboratory detection of AmpC β-lactamase: does it affect patient outcome? , 2011, American journal of clinical pathology.

[12]  M. Mallika,et al.  Prevalence and Susceptibility of extended spectrum beta-lactamases in urinary isolates of Escherichia coli in a Tertiary Care Hospital, Chennai- South India , 2011 .

[13]  I. Okeke,et al.  Quinolone resistance in Escherichia coli from Accra, Ghana , 2011, BMC Microbiology.

[14]  L. Drago,et al.  In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations , 2010, BMC Microbiology.

[15]  K. Laupland,et al.  Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern , 2008 .

[16]  David L. Steffen,et al.  Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location , 2008, BMC infectious diseases.

[17]  D. Pillay,et al.  Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. , 2006, The Journal of antimicrobial chemotherapy.

[18]  R. Cantón,et al.  The CTX-M β-lactamase pandemic , 2006 .

[19]  R. Ramphal,et al.  Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data , 2006 .

[20]  G. Fadda,et al.  Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome , 2006, Antimicrobial Agents and Chemotherapy.

[21]  A. Rattan,et al.  Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals. , 2005, Indian journal of medical microbiology.

[22]  G. Rossolini,et al.  Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. , 2005, International journal of antimicrobial agents.

[23]  A. Duarte,et al.  First Isolation of blaVIM-2 in Klebsiella oxytoca Clinical Isolates from Portugal , 2005, Antimicrobial Agents and Chemotherapy.

[24]  J. Rodríguez-Baño,et al.  Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.

[25]  V. Dubois,et al.  Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Community and Private Health Care Centers , 2003, Antimicrobial Agents and Chemotherapy.

[26]  H. Shin,et al.  Imipenem-EDTA Disk Method for Differentiation of Metallo-β-Lactamase-Producing Clinical Isolates of Pseudomonas spp. and Acinetobacter spp , 2002, Journal of Clinical Microbiology.

[27]  J. Quinn,et al.  Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Annie Wong-Beringer,et al.  Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  George A. Jacoby,et al.  Plasmid-Determined AmpC-Type β-Lactamases , 2002, Antimicrobial Agents and Chemotherapy.

[30]  P. Bradford.  Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[31]  K. Thomson.  Controversies about extended-spectrum and AmpC beta-lactamases. , 2001, Emerging infectious diseases.

[32]  D. Livermore,et al.  Detection of Extended-Spectrum β-Lactamases in Klebsiellae with the Oxoid Combination Disk Method , 2000, Journal of Clinical Microbiology.

[33]  J. Heritage,et al.  Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria. , 1999, The Journal of antimicrobial chemotherapy.

[34]  D. Sirot,et al.  TEM-24 Produced by Four Different Species ofEnterobacteriaceae, Including Providencia rettgeri, in a Single Patient , 1999, Antimicrobial Agents and Chemotherapy.

[35]  P. Nordmann,et al.  An SHV-Derived Extended-Spectrum β-Lactamase in Pseudomonas aeruginosa , 1999, Antimicrobial Agents and Chemotherapy.

[36]  K. Tateda,et al.  Efficacy of beta-lactam antibiotics combined with gentamicin against penicillin-resistant pneumococcal pneumonia in CBA/J mice. , 1999, The Journal of antimicrobial chemotherapy.

[37]  P. Courvalin,et al.  Updated Sequence Information for TEM β-Lactamase Genes , 1999, Antimicrobial Agents and Chemotherapy.

[38]  I. Casin,et al.  A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa , 1996, Antimicrobial agents and chemotherapy.

[39]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[40]  T. Palzkill,et al.  New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis , 1995, Antimicrobial agents and chemotherapy.

[41]  G. Jacoby,et al.  More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.

[42]  R. Ambler,et al.  The structure of beta-lactamases. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[43]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[44]  Stephan Mehler,et al.  Clinical Microbiology Procedures Handbook , 2016 .

[45]  K. Anuradha,et al.  Phenotypic detection of ESBL and MBL in clinical isolates of Enterobacteriaceae , 2013 .

[46]  R. Cantón,et al.  The CTX-M beta-lactamase pandemic. , 2006, Current opinion in microbiology.

[47]  R. Ramphal,et al.  Extended-spectrum beta-lactamases and clinical outcomes: current data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[49]  P. Courvalin,et al.  Updated sequence information for TEM beta-lactamase genes. , 1999, Antimicrobial agents and chemotherapy.

[50]  I. Gould,et al.  Extended spectrum beta-lactamases. , 1998, The Journal of infection.